Business

GlobalData Survey Forecasts Challenges For Pharmaceutical Industry In 2024

• By Newsdesk
• New Delhi
• Dec 25, 2023

Business

As per media reports, the recent survey titled 'The State of the Biopharmaceutical Industry 2024,' conducted by GlobalData, has brought attention to the significant challenges expected in the pharmaceutical sector in the coming year. Noteworthy issues include persistent inflation, geopolitical tensions, and the ongoing effort to reduce drug prices.

Survey participants expressed concerns about drug pricing and reimbursement constraints, with a majority anticipating negative effects in 2024. Following closely were worries about geopolitical conflicts and inflation, contributing to an environment of economic uncertainty, as reported in the media.

Senior Director of Market Research at GlobalData, Urte Jakimaviciute, reportedly highlighted the potential impact of global tensions on the pharmaceutical industry. Geopolitical conflicts, coupled with strained relationships, could lead to reduced cooperation, disruptions in the IPO market, and the imposition of economic sanctions.

The survey's findings indicate that drug pricing remains a significant challenge for the pharmaceutical sector, consistently impeding industry growth. After briefly yielding its top position to inflation in the previous year, drug pricing has regained prominence as the primary concern for 2023.

Jakimaviciute emphasized the delicate balance needed between controlling pricing and ensuring healthcare affordability for the public. While pricing controls contribute to more accessible healthcare, they also limit revenue growth for pharmaceutical companies. Rising production costs, driven by increased supplier expenses and employee expectations of higher wages, present challenges to sustaining revenue growth.

Despite inflation showing signs of receding since its peak in 2022, its lingering impact continues to affect consumers and businesses. The implementation of tighter monetary policies across diverse markets raises concerns about a potential recession or obstacles to global growth.